7-hydroxymitragynine, commonly called 7-OH, is a naturally occurring alkaloid associated with Mitragyna speciosa, the plant commonly known as kratom. While traditional kratom is usually encountered as dried leaf, powder, tea, capsules, or extracts, 7-OH has increasingly appeared in concentrated product formats, including vaping products.

Because vaping introduces a different route of exposure, it is useful to understand how these products differ from traditional kratom and what researchers currently know about them.

What Is 7-OH?

Kratom contains numerous naturally occurring alkaloids. Mitragynine is generally the predominant alkaloid, while 7-OH is normally present only in relatively small amounts in natural leaf material.

7-OH has attracted scientific interest because of its activity at the mu-opioid receptor. Research has examined its pharmacological properties, metabolism, potential for dependence, and other opioid-related effects.

The FDA distinguishes naturally occurring trace amounts of 7-OH in kratom leaf from products containing concentrated or added 7-OH.

What Is a 7-OH Vape?

A 7-OH vape is a formulation designed to deliver a kratom-related alkaloid through inhalation. Instead of swallowing a tablet or consuming botanical leaf, the formulation is heated to produce an aerosol.

This creates an important distinction from traditional kratom products.

The material inside a vape is not necessarily identical to the aerosol produced during heating. Temperature, device design, formulation ingredients, and heating conditions may influence the compounds ultimately inhaled.

For this reason, researchers studying 7-OH vapes need to consider both the original formulation and the resulting aerosol.

What Can These Products Contain?

The composition of commercial 7-OH vaping products can vary.

A formulation may contain 7-OH alongside other kratom-related alkaloids, carrier ingredients, flavoring substances, or additional active compounds.

A 2026 study examining 49 nonswallowed kratom-derived products found that 67% were vaping products. Most contained 7-OH, while some contained mitragynine extracts or mitragynine pseudoindoxyl. Several products also contained intoxicating hemp cannabinoids.

These findings demonstrate why the product name alone cannot establish its complete chemical composition.

How 7-OH Vapes Differ From Traditional Kratom

Traditional kratom is a botanical material containing a mixture of naturally occurring alkaloids. A concentrated 7-OH product, by comparison, may contain a substantially enhanced amount of one particular alkaloid.

The route of administration is also different.

Traditional kratom products are commonly consumed orally, whereas vaping exposes the respiratory system to an aerosol. These different pathways can produce different absorption and pharmacokinetic profiles.

Consequently, research involving oral kratom should not automatically be interpreted as evidence about inhaled 7-OH.

Why Testing Matters

Laboratory testing is particularly relevant when evaluating concentrated alkaloid products.

Testing may determine:

• Actual 7-OH concentration

• Mitragynine and other alkaloids

• Additional active ingredients

• Carrier materials

• Potential contaminants

• Chemical degradation products

• Differences between labeled and measured concentrations

Recent analytical research has identified substantial discrepancies between labeled and measured 7-OH concentrations in some commercial products. Researchers have also examined chemical changes associated with 7-OH degradation and oxidation.

A Certificate of Analysis can provide useful batch-specific information, but it does not establish that a product is safe for human use or inhalation.

The Importance of Aerosol Research

One of the biggest unanswered questions surrounding 7-OH vaping concerns the chemistry of the aerosol itself.

Heating a formulation can potentially produce chemical changes. Researchers therefore need to investigate whether 7-OH remains stable under vaping conditions and whether additional compounds are generated.

Relevant areas of research include:

• Thermal stability

• Degradation products

• Aerosol composition

• Particle size

• Respiratory deposition

• Device temperature

• Repeated heating

• Potential respiratory toxicity

These questions are particularly important because relatively little clinical research currently exists on inhaled 7-OH.

Current Safety Evidence

The FDA currently recommends that consumers avoid concentrated 7-OH products and states that these products have not been demonstrated to be safe or effective for any use. The agency has reported adverse effects associated with 7-OH products, including addiction, withdrawal symptoms, anxiety, depression, gastrointestinal distress, insomnia, and seizures.

Vaping adds another potential area of concern because the respiratory system is directly exposed to the resulting aerosol.

However, researchers should distinguish between established findings and research questions that remain unanswered. The exact health effects of long-term inhalation of specific 7-OH formulations require additional study.

What Researchers Still Need to Know

The scientific literature surrounding 7-OH vaping remains limited compared with research into more established pharmaceutical compounds.

Important research questions include:

Pharmacokinetics: How quickly is inhaled 7-OH absorbed, metabolized, and eliminated?

Aerosol chemistry: What compounds are produced when the formulation is heated?

Product consistency: Do different batches contain comparable concentrations?

Long-term exposure: What effects could repeated inhalation have?

Interactions: How might 7-OH interact with medications, other alkaloids, cannabinoids, or other substances?

Toxicology: What effects could the aerosol have on respiratory tissues?

Answering these questions will require controlled laboratory, toxicological, and clinical research.

Regulatory Developments

The regulatory environment surrounding concentrated 7-OH has changed rapidly.

In 2025, the FDA issued warning letters to companies marketing concentrated 7-OH products and stated that 7-OH is not lawful as a dietary supplement or conventional food ingredient.

In 2026, federal agencies continued taking action concerning concentrated 7-OH products. The FDA reported that the DEA had begun a temporary scheduling process concerning 7-OH above a proposed threshold.

State-level rules can also differ, so the legal status of a particular product should always be evaluated according to the current laws applicable to the relevant jurisdiction.

Final Thoughts

7-hydroxy kratom vapes represent a relatively new product format combining concentrated 7-OH with an inhaled delivery method. They should not automatically be considered equivalent to traditional kratom powder, capsules, or other oral products.

Their composition can vary, and heating introduces additional scientific questions involving aerosol chemistry, stability, degradation, and respiratory exposure.

Current research has identified substantial variability among commercial 7-OH products and significant gaps in human safety and pharmacokinetic data.

For anyone researching this product category, the most useful approach is to look beyond the label and consider chemical composition, independent testing, delivery route, aerosol characteristics, scientific evidence, and current regulation together.

As research continues, better analytical methods and controlled studies will be necessary to establish a clearer understanding of concentrated 7-OH vaping products and their potential effects.